Bupropion HCL ER
Notice ID:SPE2D2-21-R-0105
This is a modification to invoke option year 3 for a national contract for Bupropion HCL ER. The modification also incorporates two Department of Defense class deviations and a clause related to the Federal Acquisition Supply Chain Security Act.
Department/Ind.Agency
Subtier
Office
DEPT OF DEFENSE
DEFENSE LOGISTICS AGENCY
DLA TROOP SUPPORT
PSC
6505 DRUGS AND BIOLOGICALS
LOCATION:
Not Given
Primary Contact
Kyle Lewicki
445-***-0977
Alt Contact
Jason C. Wray
445-***-6304
Links (0)
Attachments (15)
Document
Size
Access
Updated
Modification P00008 SPE2D223D0002 Option Year 3.PDF
24.54 KB
Public
Sep 15, 2025
Modification P00007 SPE2D223D0002.PDF
196.51 KB
Public
Sep 15, 2025
Modification P00006 SPE2D223D0002 Option Year 2.PDF
24.55 KB
Public
Sep 13, 2024
Modification P00005 SPE2D223D0002.PDF
187.8 KB
Public
Sep 13, 2024
Signed SPE2D223D0002 P00003.pdf
174.69 KB
Public
Sep 13, 2024
SF30_SPE2D223D0002P00004.PDF Signed.pdf
18.13 KB
Public
Sep 13, 2024
Revised Schedule of Supplies.pdf
111.71 KB
Public
Sep 13, 2024
Bilaterally Signed SPE2D223D0002 P00001.pdf
192.55 KB
Public
Sep 13, 2024
Bilaterally Signed Bupropion HCL ER Award SPE2D2-23-D-0002.pdf
375.09 KB
Public
Sep 13, 2024
SPE2D221R0105 0002.pdf
104.19 KB
Public
Mar 1, 2022
REVISED Page 104 Appendix B.pdf
104.41 KB
Public
Feb 8, 2022
REVISED Pages 39 to 40.pdf
125.84 KB
Public
Feb 8, 2022
REVISED Page 2 Schedule of Supplies.pdf
68.21 KB
Public
Feb 8, 2022
SPE2D221R0105 0001.pdf
136.2 KB
Public
Feb 8, 2022
Bupropion HCL ER National Contracts Solicitation SPE2D2-21-R-0105.pdf
1.57 MB
Public
Jan 11, 2022
Data sourced from SAM.gov.
View Official Posting »